The influence of bevacizumab on the costs of ovarian cancer treatment in routine clinical practice

Authors

  • Riikka-Liisa K. Vuorinen Department of Obstetrics and Gynecology, and Tays Cancer Center, Tampere University Hospital, Tampere, Finland; ;Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
  • Tiina H. Luukkaala Research, Development and Innovation Center, Tampere University Hospital, Tampere, Finland; ;Faculty of Social Sciences, Tampere University, Tampere, Finland
  • Johanna U. Mäenpää Department of Obstetrics and Gynecology, and Tays Cancer Center, Tampere University Hospital, Tampere, Finland; ;Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland

DOI:

https://doi.org/10.1080/0284186X.2019.1711175

Abstract

No abstract available

Downloads

Download data is not yet available.

Downloads

Published

2020-04-02

How to Cite

Vuorinen, R.-L. K. ., Luukkaala, T. H. ., & Mäenpää, J. U. . (2020). The influence of bevacizumab on the costs of ovarian cancer treatment in routine clinical practice. Acta Oncologica, 59(4), 453–457. https://doi.org/10.1080/0284186X.2019.1711175

Issue

Vol. 59 No. 4 (2020): Acta Oncologica

Section

Articles